Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Functional Restoration and Integrative Therapies in Service Members With Neuromusculoskeletal Injury

10 de outubro de 2022 atualizado por: Ardith Doorenbos, University of Washington

Determinants of the Optimal Dose and Sequence of Functional Restoration and Integrative Therapies in Service Members With Neuromusculoskeletal Injury

This study will (1) compare the effectiveness of standard rehabilitative pain care with complementary and integrative pain therapies; (2) identify subgroups of patients who do and do not respond to the intervention(s); (3) determine the most effective sequencing of the interventions; and (4) determine factors associated with treatment response that can be implemented to support clinical decision-making.

Visão geral do estudo

Descrição detalhada

Objectives and Rationale. Pain due to neuromusculoskeletal injuries is a leading cause of disability among active duty military Service members. The injury rate is significant with 628 neuromusculoskeletal injuries per 1000 person-years among active duty military Service members. Neuromusculoskeletal injuries include amputations following battlefield trauma, repetitive motion injuries related to equipment use or weight-bearing postures, and even injuries or strains incurred during off-duty pursuits. Regardless of cause, the effects on both individual Service members and military readiness are significant: Only 13% of Service members being treated primarily for pain ever return to the field.

The Department of Defense (DoD) has recently expanded its capacity to provide both functional restoration (FR) and complementary and integrative medicine (CIM) therapies for neuromusculoskeletal injury, pain, and disability. The proposed research aims to determine the most effective treatment combination, sequence, and duration of standard rehabilitative care (SRC), such as physical and occupational therapy in combination with cognitive behavioral therapy and CIM therapies, such as acupuncture and chiropractic, for Service members preparing to enroll in an intensive FR program that is currently the DoD-recommended treatment. In addition, this study aims to identify ways to predict in advance which patients will respond best to which therapeutic regimens.

Potential Impact. This research has the potential to determine which patients are most likely to benefit from the non-medication pain therapies currently available in all Army Interdisciplinary Pain Management Centers (IPMC) and how these therapies can most effectively be combined to achieve the greatest improvements in pain impact, quality of life and ability to return to duty following injury.

Patients Who Will Benefit. This study will involve active duty Service members referred to an Army IPMC. The results will be shared with other Military Health System (MHS) and Veterans Health Administration (VHA) pain management centers so that active duty Service members and veterans across United States may benefit from a treatment approach that is tailored to their individual characteristics. It is anticipated that the knowledge gained through this research will be applicable to family members of Service members and veterans and will ultimately lead to expansion of TRICARE benefits to include CIM therapies.

Potential Clinical Applications, Benefits, and Risks. This research will assist providers in determining when to refer their patients with neuromusculoskeletal pain for SRC and/or CIM therapies prior to FR. It will assist IPMCs in developing treatment plans tailored to the needs of each patient. Service members and veterans will benefit by being referred for these approaches when appropriate during the course of disabling chronic pain conditions. Ultimately, it is hoped that decision tools can be imbedded in the electronic medical record to guide health care providers to consider referral for these therapies in patients who may benefit. This study will advance our ability to effectively tailor therapies for rehabilitation from neuromusculoskeletal pain for different patients to yield the greatest benefit in physical function and quality of life. The risks of these interventions are minimal; Service members may experience general muscle soreness for the first week or so of increased physical activity, but this typically resolves.

Projected Timeline. This research will determine the optimal combination, sequence, and duration of therapies. It is expected that some active duty Service members could see improvements in function and quality of life within three weeks, but others may require up to six weeks to experience meaningful improvement.

Benefit to Military Personnel. This research will benefit Service members experiencing pain due to neuromusculoskeletal injury. It will identify ways to direct them to the therapies most likely to yield meaningful improvements in function and quality of life, and thus facilitate their return to duty. The recommendations from this study will be shared with pain management centers throughout the DoD, VHA; and, we hope, eventually to TRICARE members.

Tipo de estudo

Intervencional

Inscrição (Antecipado)

280

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Washington
      • Tacoma, Washington, Estados Unidos, 98431
        • Madigan Army Medical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Active duty service members
  • Neuromusculoskeletal or neuropathic pain ≥ 3-months duration
  • Pain of sufficient severity to bring about dysfunction in daily social, vocational, and/or interpersonal activities

Exclusion Criteria:

  • Major surgeries within past 6 months or planned within next 6 months
  • Unstable psychological disorders
  • Active substance use disorder

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Complementary and Integrative Therapies
Chiropractic, Acupuncture, Yoga, Biofeedback (if indicated), and Foam roller instruction
Intervention time period is 3 - 6 weeks.
Comparador Ativo: Standard Rehabilitative Care
Cognitive Behavioral Therapy (CBT) 60-minute orientation, CBT psychoeducation group, and Physical therapy/occupational therapy
Intervention time period is 3 - 6 weeks.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline Pain Intensity
Prazo: 3 months
Pain Intensity 10-pt Numeric Rating Scale
3 months
Change from Baseline Pain Impact
Prazo: 3 months
Aggregate score calculated from Defense and Veterans Pain Rating Scale (DVPRS)
3 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Depression
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Reported Outcome Measurement Information System
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Anxiety
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Reported Outcome Measurement Information System
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Emotional Distress - Anger
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Reported Outcome Measurement Information System
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Sleep Disturbance
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Reported Outcome Measurement Information System
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Fatigue
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Reported Outcome Measurement Information System
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
PTSD
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Primary Care PTSD Screen
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Activation Measure
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
A 22-item survey that addresses four stages of patient activation: (1) believing the patient role is important, (2) having the confidence and knowledge necessary to take action, (3) actually taking action to maintain and improve one's health, and (4) staying the course even under stress. Patients are asked to agree or not to agree with each of the 22 items.
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Drug Use
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Drug Use Questionnaire
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Pain Catastrophizing
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Pain Catastrophizing Scale
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Kinesiophobia
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Tampa Scale for Kinesiophobia
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Pain Self-Efficacy
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Pain Self Efficacy Questionnaire
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Chronic Pain Acceptance
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Chronic Pain Acceptance Questionnaire
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Functional Capacity
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Roland-Morris Disability Questionnaire and Canadian Occupational Performance Measure
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Opioid Utilization
Prazo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Opioid Utilization Screener
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Cortisol
Prazo: baseline, 6 weeks
Salivary Cortisol
baseline, 6 weeks
Oxidative Stress
Prazo: baseline, 6 weeks
Urine Sample
baseline, 6 weeks
Genomic DNA
Prazo: baseline
Buccal Sample
baseline
Army Physical Fitness Test (APFT)
Prazo: baseline, 6 weeks, 3 months, 6 months
Passing scores of 60 on all 3 components (push-ups, sit-ups, 2-mile run) of the APFT will be operationalized as "force-readiness".
baseline, 6 weeks, 3 months, 6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Ardith Z Doorenbos, RN, PhD, University of Washington

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

15 de junho de 2018

Conclusão Primária (Antecipado)

30 de junho de 2023

Conclusão do estudo (Antecipado)

31 de dezembro de 2023

Datas de inscrição no estudo

Enviado pela primeira vez

8 de agosto de 2017

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de setembro de 2017

Primeira postagem (Real)

29 de setembro de 2017

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de outubro de 2022

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de outubro de 2022

Última verificação

1 de outubro de 2022

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • STUDY00004220

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

3
Se inscrever